Humana (NYSE:HUM) had its price target decreased by Credit Suisse Group from $352.00 to $315.00 in a report released on Thursday, The Fly reports. Credit Suisse Group currently has an outperform rating on the insurance provider’s stock.
HUM has been the topic of a number of other reports. UBS Group began coverage on Humana in a research note on Tuesday, April 23rd. They issued a neutral rating and a $266.00 price target on the stock. Stephens started coverage on Humana in a research note on Monday, January 14th. They set an overweight rating and a $336.00 price objective on the stock. Zacks Investment Research lowered Humana from a buy rating to a hold rating in a research note on Friday, February 8th. Citigroup lowered their price objective on Humana from $362.00 to $302.00 and set a buy rating on the stock in a research note on Thursday. Finally, Cowen raised Humana from a market perform rating to an outperform rating and set a $275.02 price objective on the stock in a research note on Friday, January 11th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $337.26.
Shares of NYSE:HUM traded up $2.12 during trading on Thursday, reaching $249.50. The stock had a trading volume of 1,361,400 shares, compared to its average volume of 1,316,058. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.68 and a quick ratio of 1.68. The firm has a market capitalization of $34.64 billion, a PE ratio of 17.15, a P/E/G ratio of 1.05 and a beta of 0.88. Humana has a 1-year low of $225.65 and a 1-year high of $355.88.
The firm also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.55 dividend. The ex-dividend date is Thursday, June 27th. This represents a $2.20 dividend on an annualized basis and a yield of 0.88%. Humana’s dividend payout ratio is currently 15.12%.
In other Humana news, insider Christopher H. Hunter sold 15,586 shares of Humana stock in a transaction on Monday, February 25th. The stock was sold at an average price of $305.24, for a total value of $4,757,470.64. Following the sale, the insider now owns 28,100 shares in the company, valued at $8,577,244. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Roy A. Beveridge sold 8,278 shares of Humana stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $307.16, for a total value of $2,542,670.48. Following the completion of the sale, the insider now owns 12,409 shares in the company, valued at approximately $3,811,548.44. The disclosure for this sale can be found here. 0.54% of the stock is owned by insiders.
Large investors have recently bought and sold shares of the business. Stephens Inc. AR raised its holdings in shares of Humana by 48.5% in the 4th quarter. Stephens Inc. AR now owns 1,369 shares of the insurance provider’s stock valued at $392,000 after buying an additional 447 shares during the period. Pacer Advisors Inc. raised its holdings in shares of Humana by 6,493.6% in the 1st quarter. Pacer Advisors Inc. now owns 12,396 shares of the insurance provider’s stock valued at $3,298,000 after buying an additional 12,208 shares during the period. Machina Capital S.A.S. purchased a new stake in shares of Humana in the 4th quarter valued at $809,000. Kinneret Advisory LLC purchased a new stake in shares of Humana in the 4th quarter valued at $1,031,000. Finally, Cribstone Capital Management LLC purchased a new stake in shares of Humana in the 1st quarter valued at $230,000. Institutional investors own 94.69% of the company’s stock.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Further Reading: Stochastic Momentum Index (SMI)
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.